TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Placebo-Controlled Study of Safety and Efficacy of CORLUX™ (Mifepristone) in the Treatment of Psychotic Symptoms in Patients With Major Depressive Disorder With Psychotic Features
Brief Summary: Corlux (mifepristone) is a new medication that modulates the body's use of a hormone called cortisol. Under normal conditions, cortisol and other hormones are created by the body in response to physical and emotional stress, triggering a healthy stress response. People who suffer from psychotic major depression may have unusually high levels of cortisol circulating within them or abnormal patterns of cortisol levels, overloading the stress response mechanism and causing symptoms of psychosis such as delusional thoughts or hallucinations. If Corlux can keep the body's cortisol receptors from being overloaded, the stress response system may return to normal function, which may result in improvement of symptoms. The purpose of this 56 day study is to learn the safety and effectiveness of Corlux in patients who have been diagnosed with psychotic major depression (PMD).


Options:
A: Arm Label: mifepristone 600 mg; Type: EXPERIMENTAL; Interventions: Drug: Mifepristone | Arm Label: matching placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Mifepristone; Assigned to Arm(s): mifepristone 600 mg | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): matching placebo
B: Arm Label: mifepristone 600 mg; Type: EXPERIMENTAL; Interventions: Drug: Mifepristone | Arm Label: matching placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: matching placebo | Intervention Type: DRUG; Name: Mifepristone; Assigned to Arm(s): mifepristone 600 mg | Intervention Type: DRUG; Name: matching placebo; Assigned to Arm(s): matching placebo
C: Arm Label: olanzapine/sertraline combination; Type: ACTIVE_COMPARATOR; Interventions: Drug: Olanzapine, Drug: Sertraline | Arm Label: olanzapine plus placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Olanzapine, Other: placebo | Intervention Type: DRUG; Name: Olanzapine; Assigned to Arm(s): olanzapine plus placebo, olanzapine/sertraline combination | Intervention Type: DRUG; Name: Sertraline; Assigned to Arm(s): olanzapine/sertraline combination | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): olanzapine plus placebo
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: mifepristone | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: mifepristone; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Buprenorphine Effectiveness Evaluation in HIV Enhancement (BEEHIVE): A Randomized Trial of HIV Clinic-based Buprenorphine/Naloxone vs. Case Management and Referral in Opioid-dependent Individuals
Brief Summary: The purpose of this study is to compare the effectiveness of two approaches to treating HIV-infected patients who are addicted to opioid drugs (e.g., heroin) in an inner-city HIV clinic. The two approaches are:

* Case management and referral - participants are managed by a case manager and referred to a specialized drug treatment center where they receive counseling and medications for opioid-dependence (e.g., methadone or buprenorphine); or
* Clinic-based treatment - participants receive counseling and treatment with buprenorphine at the HIV clinic.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Clinic-based substance abuse treatment with buprenorphine | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Case management and referred substance abuse treatment | Intervention Type: BEHAVIORAL; Name: Clinic-based substance abuse treatment with buprenorphine; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Case management and referred substance abuse treatment; Assigned to Arm(s): 2
B: Intervention Type: DRUG; Name: Buprenorphine/Subutex; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Naltrexone; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: Drug counseling; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: Buprenorphine/naloxone; Assigned to Arm(s): N/A
D: Arm Label: Buprenorphine/Nx with EMM; Type: EXPERIMENTAL; Interventions: Behavioral: Enhanced Medical Management (EMM) of Prescription Opiate Abuse | Arm Label: Buprenorphine/Nx with SMM; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard Medical Management (SMM) of Prescription Opiate Abuse | Intervention Type: BEHAVIORAL; Name: Standard Medical Management (SMM) of Prescription Opiate Abuse; Assigned to Arm(s): Buprenorphine/Nx with SMM | Intervention Type: BEHAVIORAL; Name: Enhanced Medical Management (EMM) of Prescription Opiate Abuse; Assigned to Arm(s): Buprenorphine/Nx with EMM

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A SU011248 Expanded Access Protocol For Systemic Therapy Of Patients With Metastatic Renal Cell Carcinoma Who Are Ineligible For Participation In Other SU011248 Protocols But May Derive Benefit From Treatment With SU011248
Brief Summary: The primary objective of this protocol is to provide access to SU011248 treatment for patients with metastatic RCC who are ineligible for participation in ongoing SU011248 clinical studies and have the potential to derive clinical benefit from treatment with SU011248 based on the judgment of the investigator.


Options:
A: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Interferon Alfa | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: CCI-779 | Arm Label: C; Type: EXPERIMENTAL; Interventions: Drug: Interferon Alfa and CCI-779 | Intervention Type: DRUG; Name: Interferon Alfa; Assigned to Arm(s): A | Intervention Type: DRUG; Name: CCI-779; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Interferon Alfa and CCI-779; Assigned to Arm(s): C
B: Intervention Type: DRUG; Name: Sutent; Assigned to Arm(s): N/A
C: Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Interferon-alfa | Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: SU011248 | Intervention Type: DRUG; Name: Interferon-alfa; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: SU011248; Assigned to Arm(s): 1
D: Arm Label: SU011248 (sunitinib); Type: EXPERIMENTAL; Interventions: Drug: SU011248 (sunitinib) | Intervention Type: DRUG; Name: SU011248 (sunitinib); Assigned to Arm(s): SU011248 (sunitinib)

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized, Double Blind, Placebo Controlled Trial of Albendazole in Soil-Transmitted Helminth and HIV-1 co-Infected Kenyan Individuals to Determine the Effect of Such Treatment on HIV-1 Disease Progression and Genital Shedding.
Brief Summary: Identifying methods to slow disease progression in patients with HIV-1 infection remains a top priority in many regions of the world. In many countries, medications known to slow progression are not readily affordable or available. Many of the individuals living in these countries are also co-infected with a variety of other diseases such as tuberculosis, malaria and soil-transmitted helminths. There are data to suggest that infection with these agents may activate the immune system in HIV-1 co-infected individuals and may lead to more rapid HIV disease progression. This study will evaluate the potential impact of treating helminths in HIV-1 seropositive individuals. Markers of disease progression and immune activation will be assessed. We will also measure the amount of virus in genital secretions to determine if treatment of co-infection can reduce the infectiousness of HIV in these individuals.


Options:
A: Arm Label: Single dose of mebendazole; Type: ACTIVE_COMPARATOR; Interventions: Drug: Treatment with one of the two regimens of mebendazole | Arm Label: Multiple dose of mebendazole; Type: ACTIVE_COMPARATOR; Interventions: Drug: Treatment with one of the two regimens of mebendazole | Intervention Type: DRUG; Name: Treatment with one of the two regimens of mebendazole; Assigned to Arm(s): Multiple dose of mebendazole, Single dose of mebendazole
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Albendazole | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Albendazole; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
C: Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: vitamin A supplement; Type: ACTIVE_COMPARATOR; Interventions: Drug: vitamin A supplements | Intervention Type: DRUG; Name: vitamin A supplements; Assigned to Arm(s): vitamin A supplement | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo
D: Intervention Type: DRUG; Name: Anti-helminthic; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: meglumine antimony; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized, Double Blind, Placebo Controlled Trial of Albendazole in Soil-Transmitted Helminth and HIV-1 co-Infected Kenyan Individuals to Determine the Effect of Such Treatment on HIV-1 Disease Progression and Genital Shedding.
Brief Summary: Identifying methods to slow disease progression in patients with HIV-1 infection remains a top priority in many regions of the world. In many countries, medications known to slow progression are not readily affordable or available. Many of the individuals living in these countries are also co-infected with a variety of other diseases such as tuberculosis, malaria and soil-transmitted helminths. There are data to suggest that infection with these agents may activate the immune system in HIV-1 co-infected individuals and may lead to more rapid HIV disease progression. This study will evaluate the potential impact of treating helminths in HIV-1 seropositive individuals. Markers of disease progression and immune activation will be assessed. We will also measure the amount of virus in genital secretions to determine if treatment of co-infection can reduce the infectiousness of HIV in these individuals.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Albendazole | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Albendazole; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Albendazole, Drug: Praziquantel | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Current standard of care in Kenya | Intervention Type: DRUG; Name: Albendazole; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Praziquantel; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Current standard of care in Kenya; Assigned to Arm(s): 2
C: Arm Label: Albendazole; Type: ACTIVE_COMPARATOR; Interventions: Drug: Albendazole | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Albendazole; Assigned to Arm(s): Albendazole | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Albendazole; Type: ACTIVE_COMPARATOR; Interventions: Drug: Albendazole | Arm Label: ivermectin; Type: EXPERIMENTAL; Interventions: Drug: Ivermectin | Arm Label: ivermectin 2 doses; Type: EXPERIMENTAL; Interventions: Drug: ivermectin | Intervention Type: DRUG; Name: Ivermectin; Assigned to Arm(s): ivermectin | Intervention Type: DRUG; Name: ivermectin; Assigned to Arm(s): ivermectin 2 doses | Intervention Type: DRUG; Name: Albendazole; Assigned to Arm(s): Albendazole

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Risperidone Long-Acting for Alcohol and Schizophrenia Treatment (R-LAST)
Brief Summary: The purpose of this study is to compare the efficacy of oral risperidone (Risperdal) to risperidone long-acting (Consta) in reducing alcohol use in persons diagnosed with schizophrenia or schizoaffective disorder.


Options:
A: Arm Label: Olanzapine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Olanzapine, Drug: Quetiapine, Drug: Ziprasidone | Arm Label: Quetiapine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Olanzapine, Drug: Risperidone, Drug: Ziprasidone | Arm Label: Risperidone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Olanzapine, Drug: Ziprasidone | Arm Label: Ziprasidone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Olanzapine, Drug: Ziprasidone | Intervention Type: DRUG; Name: Olanzapine; Assigned to Arm(s): Olanzapine, Quetiapine, Risperidone, Ziprasidone | Intervention Type: DRUG; Name: Quetiapine; Assigned to Arm(s): Olanzapine | Intervention Type: DRUG; Name: Risperidone; Assigned to Arm(s): Quetiapine | Intervention Type: DRUG; Name: Ziprasidone; Assigned to Arm(s): Olanzapine, Quetiapine, Risperidone, Ziprasidone
B: Arm Label: Risperidone Long Acting; Type: EXPERIMENTAL; Interventions: Drug: Risperidone Long Acting | Arm Label: Oral Risperidone; Type: ACTIVE_COMPARATOR; Interventions: Drug: oral risperidone | Intervention Type: DRUG; Name: Risperidone Long Acting; Assigned to Arm(s): Risperidone Long Acting | Intervention Type: DRUG; Name: oral risperidone; Assigned to Arm(s): Oral Risperidone
C: Intervention Type: DRUG; Name: risperidone; quetiapine; Assigned to Arm(s): N/A
D: Arm Label: 001; Type: EXPERIMENTAL; Interventions: Drug: Risperidone Long Acting Injectable (LAI) | Arm Label: 002; Type: ACTIVE_COMPARATOR; Interventions: Drug: Quetiapine | Arm Label: 003; Type: OTHER; Interventions: Drug: Aripiprazole | Intervention Type: DRUG; Name: Aripiprazole; Assigned to Arm(s): 003 | Intervention Type: DRUG; Name: Risperidone Long Acting Injectable (LAI); Assigned to Arm(s): 001 | Intervention Type: DRUG; Name: Quetiapine; Assigned to Arm(s): 002

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multi-center Evaluation of the Experimental Program for Physical Activity Promotion (PEPAF), Carried Out by Family Physicians
Brief Summary: The potential health gains from active lifestyles are very well-known and it is recommended that all adults dedicate at least 30 minutes to activities of at least moderate intensity at least five days a week. What is still not known is how to help sedentary people follow this recommendation, by means of brief interventions feasible in routine general practice. This multi-center study was designed to evaluate the effectiveness of a physical activity promotion program (called PEPAF) implemented in 56 general practices of the Spanish public primary health care system. The study will test the capacity of the program to increase the physical activity level, physical fitness and health related quality of life of sedentary people.


Options:
A: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Mini Booster; Type: EXPERIMENTAL; Interventions: Behavioral: Mini Booster | Arm Label: Full Booster; Type: EXPERIMENTAL; Interventions: Behavioral: Full Booster | Intervention Type: BEHAVIORAL; Name: Mini Booster; Assigned to Arm(s): Mini Booster | Intervention Type: BEHAVIORAL; Name: Full Booster; Assigned to Arm(s): Full Booster
B: Intervention Type: BEHAVIORAL; Name: Internet and print-based interventions; Assigned to Arm(s): N/A
C: Arm Label: PEPAF; Type: EXPERIMENTAL; Interventions: Behavioral: Experimental Programme for Physical Activity Promotion | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Control | Intervention Type: BEHAVIORAL; Name: Experimental Programme for Physical Activity Promotion; Assigned to Arm(s): PEPAF | Intervention Type: BEHAVIORAL; Name: Control; Assigned to Arm(s): Control
D: Intervention Type: BEHAVIORAL; Name: Physical activity (PA) and immigrants; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multi-center Evaluation of the Experimental Program for Physical Activity Promotion (PEPAF), Carried Out by Family Physicians
Brief Summary: The potential health gains from active lifestyles are very well-known and it is recommended that all adults dedicate at least 30 minutes to activities of at least moderate intensity at least five days a week. What is still not known is how to help sedentary people follow this recommendation, by means of brief interventions feasible in routine general practice. This multi-center study was designed to evaluate the effectiveness of a physical activity promotion program (called PEPAF) implemented in 56 general practices of the Spanish public primary health care system. The study will test the capacity of the program to increase the physical activity level, physical fitness and health related quality of life of sedentary people.


Options:
A: Arm Label: PA intervention and Maintenance plus; Type: EXPERIMENTAL; Interventions: Behavioral: Mobile phone based physical activity intervention with maintenance plus | Arm Label: PA intervention and Maintenance regular; Type: EXPERIMENTAL; Interventions: Behavioral: Mobile phone based physical activity intervention with maintenance regular | Arm Label: Pedometer; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Control (pedometer only) | Intervention Type: BEHAVIORAL; Name: Mobile phone based physical activity intervention with maintenance plus; Assigned to Arm(s): PA intervention and Maintenance plus | Intervention Type: BEHAVIORAL; Name: Mobile phone based physical activity intervention with maintenance regular; Assigned to Arm(s): PA intervention and Maintenance regular | Intervention Type: BEHAVIORAL; Name: Control (pedometer only); Assigned to Arm(s): Pedometer
B: Arm Label: PEPAF; Type: EXPERIMENTAL; Interventions: Behavioral: Experimental Programme for Physical Activity Promotion | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Control | Intervention Type: BEHAVIORAL; Name: Experimental Programme for Physical Activity Promotion; Assigned to Arm(s): PEPAF | Intervention Type: BEHAVIORAL; Name: Control; Assigned to Arm(s): Control
C: Intervention Type: BEHAVIORAL; Name: Internet and print-based interventions; Assigned to Arm(s): N/A
D: Arm Label: FlexToBa physical activity DVD; Type: EXPERIMENTAL; Interventions: Behavioral: Home-based, DVD-delivered physical activity | Arm Label: Usual care-Wait list; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Usual care/Wait list | Intervention Type: BEHAVIORAL; Name: Home-based, DVD-delivered physical activity; Assigned to Arm(s): FlexToBa physical activity DVD | Intervention Type: BEHAVIORAL; Name: Usual care/Wait list; Assigned to Arm(s): Usual care-Wait list

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multi-center Evaluation of the Experimental Program for Physical Activity Promotion (PEPAF), Carried Out by Family Physicians
Brief Summary: The potential health gains from active lifestyles are very well-known and it is recommended that all adults dedicate at least 30 minutes to activities of at least moderate intensity at least five days a week. What is still not known is how to help sedentary people follow this recommendation, by means of brief interventions feasible in routine general practice. This multi-center study was designed to evaluate the effectiveness of a physical activity promotion program (called PEPAF) implemented in 56 general practices of the Spanish public primary health care system. The study will test the capacity of the program to increase the physical activity level, physical fitness and health related quality of life of sedentary people.


Options:
A: Arm Label: Tailored Physical Activity Intervention Group; Type: EXPERIMENTAL; Interventions: Behavioral: Tailored Physical Activity Intervention | Arm Label: No Tailored Physical Activity Intervention Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Tailored Physical Activity Intervention; Assigned to Arm(s): Tailored Physical Activity Intervention Group
B: Arm Label: Intervention Group; Type: EXPERIMENTAL; Interventions: Behavioral: Phone counseling with written materials | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Phone counseling with written materials; Assigned to Arm(s): Intervention Group
C: Arm Label: CG; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Health educational program | Arm Label: IG; Type: EXPERIMENTAL; Interventions: Behavioral: Physical activity intervention | Intervention Type: BEHAVIORAL; Name: Physical activity intervention; Assigned to Arm(s): IG | Intervention Type: BEHAVIORAL; Name: Health educational program; Assigned to Arm(s): CG
D: Arm Label: PEPAF; Type: EXPERIMENTAL; Interventions: Behavioral: Experimental Programme for Physical Activity Promotion | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Control | Intervention Type: BEHAVIORAL; Name: Experimental Programme for Physical Activity Promotion; Assigned to Arm(s): PEPAF | Intervention Type: BEHAVIORAL; Name: Control; Assigned to Arm(s): Control

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Lungwena Child Nutrition Intervention Study 3, LCNI-3. A Single-Centre Intervention Trial in Rural Malawi, Testing the Anthropometric and Health Benefits of Provision of Ready to - Use - Therapeutic Food RUTF as a Complementary Food
Brief Summary: This study tests the hypothesis that infants receiving fortified spread as a complementary food for one year grow better and do not become malnourished as often as infants who are provided with maize-soy flour for complementary porridge.


Options:
A: Intervention Type: DIETARY_SUPPLEMENT; Name: No food supplement; Assigned to Arm(s): N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: Food supplement: fortified spread; Assigned to Arm(s): N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: Food supplement: maize-soy flour; Assigned to Arm(s): N/A
B: Intervention Type: DIETARY_SUPPLEMENT; Name: fortified spread (RUTF); Assigned to Arm(s): N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: maize and soy flour; Assigned to Arm(s): N/A
C: Arm Label: Current protocol; Type: ACTIVE_COMPARATOR; Interventions: Other: Current protocol | Arm Label: Integrated Protocol; Type: EXPERIMENTAL; Interventions: Other: Integrated Protocol | Intervention Type: OTHER; Name: Integrated Protocol; Assigned to Arm(s): Integrated Protocol | Intervention Type: OTHER; Name: Current protocol; Assigned to Arm(s): Current protocol
D: Intervention Type: DIETARY_SUPPLEMENT; Name: PlumpyNut; Assigned to Arm(s): N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: PlumpyDoz; Assigned to Arm(s): N/A

Answer: B